The use of adalimumab reduces the need for use of corticosteroids in active and inactive form of noninfectious uveitis, according to a study by scientists from the University of Melbourne in Australia.
Within a multicenter retrospective study was studied the state of 37 eyes from 22 patients with refractory non-infectious uveitis under therapy adalimumab: 55% suffered from either posterior uveitis or panuveitis. Mean duration of uveitis at the initial stage of the study was 83.2 months, and most patients (68%) already were being treated with prednisolone and at least two standard immunosuppressive agents.
After six weeks of therapy with oral dose of prednisolone was reduced to 10 mg/day or less in nine of 12 (75%) patients.
To six months from nine eyes (90%) with the active form of the disease was observed two-step reduction of inflammation of the anterior chamber, and six eyes (60%) had a similar improvement in the vitreous body. During this same time, almost all eyes (94%) with an inactive form of the disease remained clinically calm. The development of serious side effects were reported.
“The results show that adalimumab can be effective even as a third line therapy for refractory cases of noninfectious uveitis,” said the authors of the work published in the journal British Journal of Ophthalmology. Significance of the study also was to expand the potential patient population for which the therapy adalimumab can have advantages – patients with back and front uveitis.
However, as in the study of the VISUAL, “we found still a significant proportion of patients who did not complete the course of treatment adalimumab due to the recurrence of uveitis occurred in the later phase of adalimumab treatment. The reasons for late failure of treatment is still unclear,” write the researchers.
All the news of the Russian and world medicine in our Telegram channel @MedicineNews.